首页> 美国卫生研究院文献>Molecular Medicine >A Superagonistic Monoclonal Antibody for CD28 Ameliorates Crescentic Glomerulonephritis in Wistar-Kyoto Rats
【2h】

A Superagonistic Monoclonal Antibody for CD28 Ameliorates Crescentic Glomerulonephritis in Wistar-Kyoto Rats

机译:CD28的超激动剂单克隆抗体可改善Wistar-Kyoto大鼠的新月形肾小球肾炎

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Regulatory T (Treg) cells play an important role in the resolution of crescentic glomerulonephritis, where a T helper 1 (Th1)-predominant immune response promotes crescent formation. Therefore, agents that increase Treg cells appear to be ideal for suppressing T-cell-mediated renal pathology. We hypothesized that a superagonistic monoclonal antibody for CD28 (JJ316), which has been known to preferentially expand Treg cells in vivo, could prevent nephrotoxic serum–induced nephritis in Wistar-Kyoto rats, one of the experimental models of crescentic glomerulonephritis. Administration of JJ316 attenuated crescent formation, proteinuria and glomerular accumulation of macrophages and CD8+ T cells. These changes were accompanied by increased infiltration of Treg cells. Among glomerular macrophages, the CD163+ subset was significantly increased after treatment, suggesting that Treg cells may modulate the phenotype of macrophages leading to resolution of glomerulonephritis. In an adoptive transfer experiment, two T-cell subsets (CD4+CD25+ and CD4+CD25 T cells) purified from spleens and lymph nodes of donor rats primed with JJ316 3 d before were inoculated into nephritic recipient rats, which recapitulated the beneficial effects of in vivo administration of JJ316. Furthermore, a single injection of JJ316 administered 3 d after disease induction completely protected nephritic rats from death for 2 months. In conclusion, we demonstrated that treatment with JJ316 has a dramatic therapeutic effect on an experimental crescentic glomerulonephritis, possibly due to expansion and activation of Treg cells.
机译:调节性T(Treg)细胞在新月形肾小球肾炎的解决中起着重要作用,其中以T辅助1(Th1)为主的免疫反应促进新月形的形成。因此,增加Treg细胞的药物似乎是抑制T细胞介导的肾脏病理的理想药物。我们假设CD28的超激动性单克隆抗体(JJ316)可在体内优先扩增Treg细胞,可以预防Wistar-Kyoto大鼠的肾毒性血清诱发的肾炎,这是新月型肾小球肾炎的实验模型之一。施用JJ316可减轻巨噬细胞和CD8 + T细胞的新月形形成,蛋白尿和肾小球积聚。这些变化伴随着Treg细胞浸润的增加。在肾小球巨噬细胞中,治疗后CD163 + 亚群显着增加,提示Treg细胞可能调节巨噬细胞表型,导致肾小球肾炎消退。在过继转移实验中,两个T细胞亚群(CD4 + CD25 + 和CD4 + CD25 - T从JJ316 3天前接种的供体大鼠的脾脏和淋巴结中纯化得到的细胞被接种到肾性受体大鼠中,这概括了体内施用JJ316的有益作用。此外,在诱发疾病后3天单次注射JJ316可以完全保护肾病大鼠2个月的死亡。总之,我们证明了用JJ316进行的治疗对实验性新月形肾小球肾炎具有显着的治疗作用,这可能是由于Treg细胞的扩增和活化所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号